Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis José María Álvaro-Gracia Álvaro; Petra Díaz del Campo Fontecha; José Luis Andréu Sánchez; Alejandro Balsa Criado; Rafael Cáliz Cáliz; Isabel Castrejón Fernández; Hèctor Corominas; José A. Gómez Puerta; Sara Manrique Arija; Natalia Mena Vázquez; Ana Ortiz García; Chamaida Plasencia Rodríguez; Lucía Silva Fernández; Jesús Tornero Molina;

The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui; Hong-Thinh Lai; Thanh-Lam Nguyen; Thuy-Duong Vu; Nhat-Le Bui; Van-Hung Nguyen; Thi-To-Chau Tran; Thi-Phuong-Thuy Nguyen; Thi-Ngoc-Lan Nguyen; Jaffar A. Al-Tawfiq; Dinh-Toi Chu;

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;